ProCE Banner Activity

Frequently Asked Questions in Multiple Myeloma Treatment

Clinical Thought
I answer some frequently asked questions on the care of patients with multiple myeloma; topics include treatment of smoldering myeloma, individualized therapy for newly diagnosed disease, optimal therapy at relapse, and incorporating new therapies into treatment approaches.

Released: March 02, 2020

Expiration: March 01, 2021

No longer available for credit.

Share

Faculty

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

Supported by educational grants from

Celgene

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Takeda Oncology

The Binding Site

Partners

IMF 2018

ProCE Banner

Faculty Disclosure

Primary Author

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD, has disclosed that he has received consulting fees from Legend Biotech and funds for research support from Amgen, Johnson & Johnson/Janssen, Sanofi, and Seattle Genetics.